H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3 from $3.50 and keeps a Buy rating on the shares following the Q4 report. The firm says the Tecelra launch is gaining momentum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Therapeutics: Balancing Positive Momentum with Strategic Pauses – A Hold Rating Analysis
- Adaptimmune price target lowered to $1.75 from $3 at Guggenheim
- Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook
- Adaptimmune price target lowered to $1.40 from $3.15 at Scotiabank
- Adaptimmune price target lowered to $1.50 from $2 at Wells Fargo